TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (OTC BB: TIKRF) today announced that BioCancell reported results from a Phase I/IIa clinical trial to establish the safety, optimal dose and preliminary efficacy of BioCancell’s lead drug-candidate, BC-819, as a treatment for pancreatic cancer. The trial demonstrated a significant decrease in local pancreatic tumors and no appearance of metastatic disease in most patients treated with the higher of two dosages tested after one month and three months.
